Arena Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 62   

Articles published

ARNA 4.17 -0.01 (-0.24%)
price chart
Arena Pharmaceuticals Inc. (NASDAQ:ARNA) Fights for Share of Weight-loss Pill ...
Arena Pharmaceuticals Inc. (NASDAQ:ARNA, ARNA message board) is expected to launch its patented Belviq treatment early next year, but there are some doubts that by that time Vivus, Inc. (NASDAQ:VVUS) will have made its Qsymia something of a ...
Related articles »  
Is Arena The Next Alexion?
Even though Alexion focuses on ultra-rare diseases, there are a number of parallels to a name more familiar with retail investors, Arena Pharmaceuticals whose lead drug Belviq for the medical management of obesity was recently approved. Alexion's ...
Related articles »  
With Arena, Patience Is A Virtue
Investors in Arena Pharmaceuticals (NASDAQ:ARNA) have been patient for quite some time. Early investors ... Orexigen Therapeutics (NASDAQ:OREX) is an interesting company to watch because it could very well follow in the footsteps of Arena and Vivus.
Related articles »  
Vivus Beats Arena Pharma With Obesity Drug Launch
MOUNTAIN VIEW ( TheStreet) - Vivus (VVUS) announced the commercial launch of its weight-loss pill Qsymia Monday, beating rival Arena Pharmaceuticals (ARNA) to first reach the bulging waistbands of obese Americans. Qsymia hits (mail order) pharmacy ...
Obesity Drugs Gain Attention on FDA Backing for Therapies  Businessweek
Related articles »  
Heroes And Zeros: Arena Pharmaceuticals And Avanir Pharmaceuticals
Arena Pharmaceuticals is a clinical stage biopharmaceutical company that has discovered, developed, and moved the first anti-obesity drug through FDA approval in the last 13 years in June of 2012.
Acadia Pharmaceuticals Poised For 100% Gain By December
... a company's prospects and affording investors willing to look beyond the conventional thinking an opportunity for substantial gains can be found in the positive advisory committee vote and subsequent approval of Arena Pharmaceuticals' (NASDAQ:ARNA) ...
Arena: DEA Schedule IV Will Make Belviq The Obesity Blockbuster Drug
In addition, Arena comes with some enticing benefits for a pharmaceutical suitor - 10 year Swiss Tax Haven and R&D Write-offs.
Related articles »  
500 Million Reasons to Bet on the Future of Mannkind (MNKD, ARNA,AMGN)
... drug developer operating in the biotech sector along with Amgen (NASDAQ: AMGN) and Arena Pharmaceuticals (NASDAQ: ARNA). As uber financier Mike Milken has pointed out, the capital structure is very important for a company in rewarding investors.
Questcor Pharmaceuticals Has Significant Upside Potential
Questcor has an agreement with Bio Vectra Inc., to manufacture the API. In addition, it also has a supply agreement with Cangene BioPharma Inc., to produce commercial amounts of Acthar finished product. At present, Bio Vectra and Cangene are the sole ...
Related articles »  
Navidea Biopharmaceutical Undervalued Approaching FDA Decision
Obesity drugs from Arena Pharmaceuticals (NASDAQ:ARNA) and Vivus, Inc (NASDAQ:VVUS), Amarin Corps's (NASDAQ:AMRN) Vascepa, Horizon Pharma's (NASDAQ:HZNP) Rayos, and Talon Therapeutics (OTC:TLON) Marquibo all received FDA approval, ...